CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma

CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma

Abstract Diffuse large B-cell lymphoma (DLBCL) exhibits significant genetic heterogeneity which contributes to drug resistance, necessitating development of novel therapeutic approaches. Pharmacological inhibitors of cyclin-dependent kinases (CDK) demonstrated pre-clinical activity in DLBCL, however...

Full description

Bibliographic Details
Main Authors: Elana Thieme, Nur Bruss, Duanchen Sun, Edward C. Dominguez, Daniel Coleman, Tingting Liu, Carly Roleder, Melissa Martinez, Krystine Garcia-Mansfield, Brian Ball, Patrick Pirrotte, Lili Wang, Zheng Xia, Alexey V. Danilov
Format: Article
Language:English
Published: BMC 2023-03-01
Series:Molecular Cancer
Subjects:
CDK9
BRD4
Mediator
Super-enhancer
PI3K
Online Access:https://doi.org/10.1186/s12943-023-01762-6

Internet

https://doi.org/10.1186/s12943-023-01762-6

Similar Items